这么利好，盘前还是跌_老虎社区_美港股上老虎

米手
2020-12-17

这么利好，盘前还是跌的

BioNTech says 140,000 vaccinated in Britain so far

FRANKFURT, Dec 17 (Reuters) - Pfizer and BioNTech's COVID-19 vaccine has been given to 140,000 p

BioNTech says 140,000 vaccinated in Britain so far

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":397111485,"tweetId":"397111485","gmtCreate":1608205369647,"gmtModify":1703851749592,"author":{"id":59745147503477,"authorId":59745147503477,"authorIdStr":"59745147503477","name":"米手","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>这么利好，盘前还是跌的</p></body></html>","htmlText":"<html><head></head><body><p>这么利好，盘前还是跌的</p></body></html>","text":"这么利好，盘前还是跌的","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/397111485","repostId":2092518863,"repostType":2,"repost":{"id":"2092518863","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1608200543,"share":"https://www.laohu8.com/m/news/2092518863?lang=&edition=full","pubTime":"2020-12-17 18:22","market":"us","language":"en","title":"BioNTech says 140,000 vaccinated in Britain so far","url":"https://stock-news.laohu8.com/highlight/detail?id=2092518863","media":"Reuters","summary":"FRANKFURT, Dec 17 (Reuters) - Pfizer    and BioNTech's  COVID-19 vaccine has been given to 140,000 p","content":"<html><body><p>FRANKFURT, Dec 17 (Reuters) - Pfizer    and BioNTech's</p><p>  COVID-19 vaccine has been given to 140,000 people in Britain, and the feedback on side effects and tolerability has been reassuring, BioNTech's chief medical officer said on Thursday.</p><p>   Britain was the first to approve the shot for emergency use on Dec. 3, followed by Canada and the U.S. Food and Drug Administration. </p><p>   \"In Britain, 140,000 people have been vaccinated by now and the tolerability data are exactly as we have shown in our clinical trial,\" Chief Medical Officer Oezlem Tuereci said in a webcast call with German Chancellor Angela Merkel.</p><p>   She said side effects have been mild to moderate and short-lived and similar to those typically seen in other commonly used vaccines.</p><p>   The German biotech firm's Chief Executive Ugur Sahin said in the call that he was confident that normal life could resume by next winter.</p><p> (Reporting by Ludwig Burger; editing by Thomas Seythal)</p><p>((ludwig.burger@thomsonreuters.com; +49 30 220133634; Reuters Messaging: ludwig.burger.thomsonreuters.com@reuters.net))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech says 140,000 vaccinated in Britain so far</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech says 140,000 vaccinated in Britain so far\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2020-12-17 18:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>FRANKFURT, Dec 17 (Reuters) - Pfizer    and BioNTech's</p><p>  COVID-19 vaccine has been given to 140,000 people in Britain, and the feedback on side effects and tolerability has been reassuring, BioNTech's chief medical officer said on Thursday.</p><p>   Britain was the first to approve the shot for emergency use on Dec. 3, followed by Canada and the U.S. Food and Drug Administration. </p><p>   \"In Britain, 140,000 people have been vaccinated by now and the tolerability data are exactly as we have shown in our clinical trial,\" Chief Medical Officer Oezlem Tuereci said in a webcast call with German Chancellor Angela Merkel.</p><p>   She said side effects have been mild to moderate and short-lived and similar to those typically seen in other commonly used vaccines.</p><p>   The German biotech firm's Chief Executive Ugur Sahin said in the call that he was confident that normal life could resume by next winter.</p><p> (Reporting by Ludwig Burger; editing by Thomas Seythal)</p><p>((ludwig.burger@thomsonreuters.com; +49 30 220133634; Reuters Messaging: ludwig.burger.thomsonreuters.com@reuters.net))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BNTX":"BioNTech SE"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2092518863","content_text":"FRANKFURT, Dec 17 (Reuters) - Pfizer    and BioNTech's  COVID-19 vaccine has been given to 140,000 people in Britain, and the feedback on side effects and tolerability has been reassuring, BioNTech's chief medical officer said on Thursday.   Britain was the first to approve the shot for emergency use on Dec. 3, followed by Canada and the U.S. Food and Drug Administration.    \"In Britain, 140,000 people have been vaccinated by now and the tolerability data are exactly as we have shown in our clinical trial,\" Chief Medical Officer Oezlem Tuereci said in a webcast call with German Chancellor Angela Merkel.   She said side effects have been mild to moderate and short-lived and similar to those typically seen in other commonly used vaccines.   The German biotech firm's Chief Executive Ugur Sahin said in the call that he was confident that normal life could resume by next winter. (Reporting by Ludwig Burger; editing by Thomas Seythal)((ludwig.burger@thomsonreuters.com; +49 30 220133634; Reuters Messaging: ludwig.burger.thomsonreuters.com@reuters.net))","news_type":1},"isVote":1,"tweetType":1,"viewCount":714,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":21,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}